Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.25 Increased by +10.71% | -0.26 Increased by +3.85% |
| Mar 26, 24 | -0.28 Increased by +12.50% | -0.26 Decreased by -7.69% |
| Nov 13, 23 | -0.24 Increased by +7.69% | -0.27 Increased by +11.11% |
| Aug 8, 23 | -0.28 Decreased by -12.00% | -0.35 Increased by +20.00% |
| May 9, 23 | -0.28 Decreased by -21.74% | -0.35 Increased by +20.00% |
| Mar 27, 23 | -0.32 Increased by +23.81% | -0.25 Decreased by -28.00% |
| Nov 14, 22 | -0.26 Decreased by -160.00% | -0.23 Decreased by -13.04% |
| Aug 15, 22 | -0.25 Increased by +96.84% | -0.24 Decreased by -4.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -12.96 M Decreased by -28.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.61 M Decreased by -17.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -9.48 M Decreased by -4.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -13.86 M Decreased by -66.06% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -10.05 M Decreased by -157.53% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -9.89 M Increased by +83.88% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -9.05 M Increased by +66.47% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by -100.00% | -8.35 M Decreased by -1.01 K% | Decreased by N/A% Decreased by N/A% |